Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aimmune Therapeutics, Inc. (NASDAQ: AIMT).

Full DD Report for AIMT

You must become a subscriber to view this report.


Recent News from (NASDAQ: AIMT)

The 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock
Editor's note: Seeking Alpha is proud to welcome Sleeps Well At Night as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » They...
Source: SeekingAlpha
Date: May, 16 2018 12:00
Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018
— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for po...
Source: Business Wire
Date: May, 15 2018 08:00
Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks
Stock Research Monitor: APHB, APTO, and ABIO LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration . On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading ...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:15
Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event : Bank of...
Source: Business Wire
Date: May, 09 2018 08:00
Aimmune Therapeutics Announces First Quarter 2018 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018, cash, cash equivalents and investments totaled $331.7 million. “We ...
Source: Business Wire
Date: May, 08 2018 16:01
Backing Blackstone For A Decade - Cramer's Lightning Round (4/23/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 23. Bullish Calls Ingersoll-Rand plc (IR): This is the kind of industrial stock that works in a tightening environment. Blackstone Group (BX): Cramer has been backing the stock for 10 years...
Source: SeekingAlpha
Date: April, 24 2018 06:50
Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku, and Premier - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Genuine Parts Company (NYSE:GPC), Energizer Holdings, Inc. (NYSE:EPC), A...
Source: GlobeNewswire
Date: April, 19 2018 08:15
Aimmune Still Leads In The Peanut Allergy Race
One of the main recent stumbling blocks to upward movement in Aimmune’s (AIMT) stock has been concern coming from a perceived existential threat to Aimmune’s prospects from AnaptysBio’s (ANAB) monoclonal antibody approach to treating peanut allergy. Since the release of Ai...
Source: SeekingAlpha
Date: April, 02 2018 11:49
Institutional Top Ideas Series: Deerfield Management
In the first entry of this recently rebooted series, we took a look at top ideas from Consonance Capital (whose performance almost tripled that of the IBB during time frame we looked at). Keep in mind articles older than 10 days can only be accessed if you have a membership to ROTY or Se...
Source: SeekingAlpha
Date: March, 28 2018 18:55
NetworkNewsBreaks - Aimmune Therapeutics, Inc. (NASDAQ: AIMT) Underwriters Fully Exercise Over-Allotment Option in $202.4M Public Offering
Aimmune Therapeutics (NASDAQ: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, recently closed its underwritten public offering of 6,325,000 shares of its common stock, which includes the sale of 825,000 shares in accordance with the ful...
Source: NetworkNewsWire
Date: March, 08 2018 09:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1730.0030.0130.6029.86308,254
2017-06-2017.6318.5618.9717.13453,436
2017-06-1916.5017.6917.7816.25724,653
2017-06-1617.7716.4717.8916.44760,422
2017-06-1518.3517.9718.5917.79317,379

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1434,62881,03842.7306Short
2018-08-1323,01160,96037.7477Short
2018-08-1039,35574,57252.7745Short
2018-08-0941,66473,12656.9756Short
2018-08-0816,82725,52865.9159Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AIMT.


About Aimmune Therapeutics, Inc. (NASDAQ: AIMT)

Logo for Aimmune Therapeutics, Inc. (NASDAQ: AIMT)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,552,981,463 - 05/14/2018
  • Issue and Outstanding: 51,525,596 - 02/15/2018

 


Recent Filings from (NASDAQ: AIMT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 11 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 27 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: March, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (NASDAQ: AIMT)

Daily Technical Chart for (NASDAQ: AIMT)


Stay tuned for daily updates and more on (NASDAQ: AIMT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AIMT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AIMT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AIMT and does not buy, sell, or trade any shares of AIMT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/